Mpoudi-Etame M., Sanchez T. T., Bassega P. O., Olinga J., Pelloquin Raphael, Foalem M., Njonkep C., Mimbe E., Varloteaux M., Tongo M., Lamare N., Peeters Martine, Reynes J., Delaporte E., Koulla-Shiro S., Kouanfack C., NAMSAL ANRS Study Group. (2022). Dolutegravir versus efavirenz-400 as first-line ART in Cameroon : week 192 data of NAMSAL trial. Journal of the International AIDS Society, 25 (suppl. 3), p. 15.
Titre du document
Dolutegravir versus efavirenz-400 as first-line ART in Cameroon : week 192 data of NAMSAL trial
Mpoudi-Etame M., Sanchez T. T., Bassega P. O., Olinga J., Pelloquin Raphael, Foalem M., Njonkep C., Mimbe E., Varloteaux M., Tongo M., Lamare N., Peeters Martine, Reynes J., Delaporte E., Koulla-Shiro S., Kouanfack C., NAMSAL ANRS Study Group
Source
Journal of the International AIDS Society, 2022,
25 (suppl. 3), p. 15